A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

• Keisuke Okuno,
• Raju Kandimalla,
• Marta Mendiola,
• Francesc Balaguer,
• Luis Bujanda,
• Carlos Fernandez-Martos,
• Jorge Aparicio,
• Jaime Feliu,
• Masanori Tokunaga,
• Yusuke Kinugasa,
• Joan Maurel,
• Ajay Goel

Affiliations

Keisuke Okuno

Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center

Raju Kandimalla

Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center

Marta Mendiola

Department of Medical Oncology, La Paz University Hospital (IdiPAZ), CIBERONC, cátedra UAM-AMGEN

Francesc Balaguer

Department of Gastroenterology, Hospital Clinic de Barcelona, CIBERehd, IDIBAPS, University of Barcelona

Luis Bujanda

Department of Gastroenterology, Instituto Biodonostia, CIBERehd, Universidad del País Vasco (UPV/EHU)

Carlos Fernandez-Martos

Department of Medical Oncology, Hospital Quiron Salud

Jorge Aparicio

Department of Medical Oncology, Hospital Universitario y Politécnico La Fe

Jaime Feliu

Department of Medical Oncology, La Paz University Hospital (IdiPAZ), CIBERONC, cátedra UAM-AMGEN

Masanori Tokunaga

Department of Gastrointestinal Surgery, Tokyo Medical and Dental University

Yusuke Kinugasa

Department of Gastrointestinal Surgery, Tokyo Medical and Dental University

Joan Maurel

Translational Genomics and Targeted Therapies Group. Medical Oncology, Hospital Clinic of Barcelona, CIBERehd, IDIBAPS

Ajay Goel

Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center